Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;44(1):24-32.
doi: 10.1016/j.jgr.2019.05.005. Epub 2019 May 21.

Anti-platelet role of Korean ginseng and ginsenosides in cardiovascular diseases

Muhammad Irfan  1 , Minki Kim  1 , Man Hee Rhee  1
Affiliations
Review

Anti-platelet role of Korean ginseng and ginsenosides in cardiovascular diseases

Muhammad Irfan et al. J Ginseng Res. 2020 Jan.

Abstract

Cardiovascular diseases prevail among modern societies and underdeveloped countries, and a high mortality rate has also been reported by the World Health Organization affecting millions of people worldwide. Hyperactive platelets are the major culprits in thrombotic disorders. A group of drugs is available to deal with such platelet-related disorders; however, sometimes, side effects and complications caused by these drugs outweigh their benefits. Ginseng and its nutraceuticals have been reported to reduce the impact of thrombotic conditions and improve cardiovascular health by antiplatelet mechanisms. This review provides (1) a comprehensive insight into the available pharmacological options from ginseng and ginsenosides (saponin and nonsaponin fractions) for platelet-originated cardiovascular disorders; (2) a discussion on the impact of specific functional groups on the modulation of platelet functions and how structural modifications among ginsenosides affect platelet activation, which may further provide a basis for drug design, optimization, and the development of ginsenoside scaffolds as pharmacological antiplatelet agents; (3) an insight into the synergistic effects of ginsenosides on platelet functions; and (4) a perspective on future research and the development of ginseng and ginsenosides as super nutraceuticals.

Keywords: AA, arachidonic acid; AC, adenylyl cyclase; ADP, adenosine diphosphate; ASA, acetylsalicylic acid; ATP, adenosine triphosphate; Akt, protein kinase B; Antiplatelet; COX, cyclooxygenase; CRP, collagen-related peptide; CSF, crude saponin fraction; ERK, extracellular signal–regulated kinase; GPVI, glycoprotein VI; Ginsenosides; IC50, half maximal (50%) inhibitory concentration; IP3, inositol-1,4,5-triphosphate; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MKK4, mitogen-activated protein kinase kinase 4; MLC, myosin light chain; Nutraceutical; PAF, platelet-activating factor; PAR, proteinase-activated receptor; PI3K, phosphatidylinositol 3-kinase; PKA, protein kinase A; PKC, protein kinase C; PKG, protein kinase G; PLA2, phospholipase A2; PLCγ2, phospholipase C gamma-2; PPD, protopanaxadiol; PPT, protopanaxatriol; PT, prothrombin time; ROCK, Rho-associated protein kinase; SFK, Src family kinase; Structural modification; Syk, spleen tyrosine kinase; Synergism; TS, total saponin; TxA2, thromboxane A2; TxAS, thromboxane-A synthase; TxB2, thromboxane B2; TxR, thromboxane receptor; VASP, vasodilator-stimulated phosphoprotein; [Ca2+]i, intracellular calcium ion; aPTT, activated partial thromboplastin time; cAMP, cyclic adenosine monophosphate; cPLA2α, cytosolic phospholipase A2α; vWF, von Willebrand factor.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Mechanism of platelet activation showing intracellular signaling pathways and effects of different ginsenosides on the modulation of platelet functions that affect various receptors or downstream signaling events. AA, arachidonic acid; AC, adenylyl cyclase; Akt, protein kinase B; COX, cyclooxygenase; CSF, crude saponin fraction; IP3, inositol-1,4,5-triphosphate; MAPK, mitogen-activated protein kinase; MLC, myosin light chain; PAR, proteinase-activated receptor; PKA, protein kinase A; PKC, protein kinase C; PLA2, phospholipase A2; PLCγ2, phospholipase C gamma-2; ROCK, Rho-associated protein kinase; SFK, Src family kinase; TS, total saponin; TxAS, thromboxane synthase; TxA2, thromboxane A2; VASP, vasodilator-stimulated phosphoprotein; vWF, von Willebrand factor.
Fig. 2
Fig. 2
Chemical structures and schematic conversion of the ginsenosides with respect to the structural modification among specific functional groups. Rb1→Rg5→Rh4, Rg1→Rh1→Rp4, Re→Rg2→Rp3, Rb1→Rg3→Rh2→Rp2, and Rg3→2H-Rg3→Rp1. PPD, protopanaxadiol; PPT, protopanaxatriol.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mozaffarian D., Benjamin E.J., Go A.S., Arnett D.K., Blaha M.J., Cushman M., Das S.R., de Ferranti S., Despres J.P., Fullerton H.J. Heart disease and stroke statistics-2016 update: a report from the American heart association. Circulation. 2016;133(4) e38-360. - PubMed
    1. Pagidipati N.J., Gaziano T.A. Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement. Circulation. 2013;127(6):749–756. - PMC - PubMed
    1. Shafiq G., Tatinati S., Ang W.T., Veluvolu K.C. Automatic identification of systolic time intervals in seismocardiogram. Sci Rep. 2016;6:37524. - PMC - PubMed
    1. Gielen S., Landmesser U. The Year in Cardiology 2013: cardiovascular disease prevention. Eur Heart J. 2014;35(5):307–312. - PubMed
    1. Nichols M., Townsend N., Scarborough P., Rayner M. Cardiovascular disease in Europe: epidemiological update. Eur Heart J. 2013;34(39):3028–3034. - PubMed